AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aytu BioPharma, Inc. (AYTU) on June 12, 2024, with a report date of June 18, 2024. The filing discloses the entry into a material definitive agreement regarding the restructuring of the Company's debt facilities.
Key Financial Metrics and Debt Structure
The filing details a significant refinancing transaction involving the following terms:
- New Term Loan: A $13.0 million term loan (Eclipse Term Loan) at an interest rate of SOFR plus 7.0%.
- Term Structure: A four-year term with a seven-year straight-line amortization period, resulting in a balloon payment of approximately $5.6 million at maturity.
- Revolving Credit Facility: The maturity date was extended to four years from the closing date, and the maximum borrowing capacity was increased to $14.5 million.
- Debt Repayment: Proceeds from the new term loan were used to fully repay the prior "Avenue Debt Obligations" under the Avenue Facility Agreement.
- Outstanding Shares: As of June 18, 2024, the Company had 5,972,327 shares of common stock outstanding.
The filing does not provide specific values for revenue, net profit, operating cash flow, or liquidity ratios for the current period.
Material Changes Versus Prior Period
The primary material change is the replacement of the Avenue Facility Agreement with the new Eclipse Business Capital LLC facility. This transaction:
- Introduced new co-Borrowers, including Cherry Creek Therapeutics, Inc., Aytu Therapeutics, LLC, and PharmaFab Texas, LLC.
- Increased the potential maximum borrowing capacity of the revolving facility.
- Extended the maturity timeline for the revolving credit facility.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operational performance. The primary risk disclosed relates to the new debt obligations, specifically the interest rate exposure (SOFR + 7.0%) and the requirement to repay the remaining $5.6 million balance of the term loan at maturity.
Key Facts for Investor Verification
- Verify the current SOFR rate to calculate the effective interest cost of the new $13.0 million term loan.
- Confirm the Company's current cash position to assess its ability to service the new debt and the future $5.6 million balloon payment.
- Review the full text of the Consent, Joinder and Amendment (Exhibit 10.1) for covenants and potential competitive harm redactions.
- Monitor the utilization of the increased $14.5 million revolving credit facility.